Ladies and gentlemen, good day and welcome to the Q4 FY 2025 Earnings Conference Call of Rainbow Children's Medicare Limited, hosted by IIFL Capital. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star, then zero on your touch-tone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Rahul Jeewani from IIFL Capital. Thank you, and over to you, sir.
Hi, good morning, everyone. I welcome you all to the fourth quarter earnings conference call of Rainbow Hospitals, hosted by IIFL Capital. From Rainbow, we have with us today Dr. Ramesh Kancharla, Chairman and Managing Director, Mr. Vikas Maheshwari, Group CFO, and Mr. Saurabh Bhandari, Head Investor Relations and Group Business Analyst. Over to you, sir, for your opening comments.
Thank you, Rahul. So, good morning, everyone. It's a pleasure to speak with you all today as we discuss the performance for the fourth quarter and the financial year 2024-2025. It has been a transformative year for the Rainbow, marked by operational milestones and continued focus on delivering high-quality pediatric and perinatal care. As I reflect on the fourth quarter and the year gone by, I'm pleased to report that we have made significant progress across several areas. Here are some of the key highlights. On the operational front, performance for the fourth quarter was modest compared to the strong second and third quarters of the year. We have witnessed an unusually quiet season. Approximately about 35% of the business, which includes pediatrics outpatient department and pediatric admissions and pediatric intensive care, remained low during this period.
However, we did see a strong performance in certain segments of our business, particularly in pediatric surgery, pediatric multi-specialty care, and obstetrics. All the new beds added during the last year have been seamlessly integrated into the Rainbow network and performing well. This is visible from the performance of our new units for the quarter and full year. I'm pleased to share that we have performed the first pediatric liver transplantation successfully in our Chennai Hub Hospital. Additionally, we've secured a liver transplant license for Bangalore Hub, a step forward in our efforts to build Chennai and Bangalore as a tertiary care hubs, quaternary care hubs. It gives me immense pride to share that Rainbow has been recognized with prestigious accolades as follows: We were honored to receive the Great Place to Work with our 90% score award for the fifth time we've got the Great Place to Work award.
Empowering is a testament to our ongoing efforts to build a culture where our people feel valued, empowered, and inspired. We are proud to be recognized as an amazing workplace for excellence in people's practices and received the Best Place to Work for Women awarded by the Economic Times. Further, Newsweek recognized Rainbow as the Best Pediatric and Women's Hospital for the year. Our fertility center at Kondapur, Hyderabad, received the re-accreditation of JCI, which is a Joint Commission International. With this, Rainbow continues to have three JCI-accredited hospitals in the network and also 13 NABH hospitals in its network. Our IVF services have shown good progress, reinforcing the potential as a key growth driver for the future. Butterfly Essentials is an initiative to offer a comprehensive range of baby and women care products through the retail stores format and done well.
Recently, we have launched pilot testing to offer the products online as well. We are still encountering challenges in our international business, particularly in countries like Bangladesh, Oman, Kenya, and Sudan, where there has been a significant reduction in the issuance of healthcare permits for patients seeking medical travel. For the year, the international business revenue was INR 30.7 crores as against INR 44 crores last year. We continue to prioritize cost management, actively seeking opportunities to optimize expenses. This disciplined approach is crucial as the new hospital beds come into the operations to maintain profitability. Now, delving into the numbers, for the Q4 FY 2025, our revenue registered a growth of 8.5%, amounting to INR 370.1 crores. Similarly, our EBITDA increased by 8.7%, reaching INR 114.7 crores, while PAT registering the growth of 10.7% to INR 56.5 crores.
Our overall occupancy rate for the quarter was 46.5%, with mature hospitals achieving 52.2% occupancy and new hospitals recording 35.6% occupancy rates. Let me share some updates on the key projects. The regional hospital in Rajahmundry, Andhra Pradesh, of 100 beds is in the final stages of construction, and it's expected to commence operations by the end of Q1 FY 2026. The two new spoke hospitals in Bangalore, one is the Electronic City of 90 beds and Hennur, the 60 beds, the operations are likely to commence towards the end of Q2 FY 2026. The project work commenced at the regional hospital of Coimbatore of 130 beds and is expected to take another 20-24 months. We performed Bhoomi Puja, which is ground-breaking, at both the land parcels in Sector 44 and 56 in Gurgaon in the last week of April.
The project work is in full swing in both the sites. In addition to growth plans, I would like to highlight some key achievements that reflect our commitment to delivering high-quality pediatric and perinatal care. Let me share a couple of examples. A desperate couple traveled all the way from Myanmar, hoping to fulfill their dreams of having a baby after several attempts of fertility treatments in Myanmar. They were quite happy and excited when they received the IVF successfully in Chennai, and the pregnancy was progressing fairly smoothly. The joy was soon met with a challenge where the mother went into premature delivery, delivering a 472-gram baby, and the baby came out with very feeble signs of life. Our neonatology team, fully prepared with advanced notices and the transport systems and the simulation systems, received the baby immediately and began life-saving care.
We knew how much this child meant for these parents, spending a lot of time in Chennai. The newborn went through a full range of problems of prematurity, with extreme low birth weight and being on respiratory more than three months' time, various cycles of infections, gut problems, and requiring total parenteral nutritions. So, thanks to the 24/7 dedication of our neonatal team and unwavering trust and prayers of the parents, this tiny fighter made a remarkable recovery. Now, at six months of age, the baby is thriving well with a healthy brain, healthy gut, and healthy lungs, and is expected to have normal neurodevelopmental milestones. This incredible journey is a reminder to all of us, as we always say, that it takes a lot to treat the little. In another case, when the two rare conditions are met together in one child, it made it very complicated to diagnose.
A five-year-old child who had come to Rainbow Children's Hospital with the signs and symptoms of intestinal obstruction. On evaluation, there were no signs of obstruction but was settled with medical management. This child kept coming back to the hospital with what we call intestinal obstructions, with bilious vomiting and constipation. So, we discovered the baby has severe constipation, and the colon is not moving at all. This particular condition is kind of what we call the intestinal motility disorder, which is very, very rare. So, we also found that the child had unusually high blood pressures. This prompted us to investigate extensively, including a PET scan. The PET scan revealed there was a mass in the chest, in the mediastinum, which was subsequently removed and tested histopathologically showed undifferentiated neuroblastoma. Our oncology team believes that the outcome of the baby is fairly good with the chemotherapy.
The bowel issues are being addressed now. These cases underscore the critical role of a multidisciplinary approach in managing tertiary and quaternary care patients, which is key to achieving better outcomes. With that, I will now pass the mic to our Group CFO, Mr. Vikas Maheshwari, to take you through the financial update. Thank you once again for joining us today. So, we look forward to your questions and insights as we move forward. Thank you, Vikas.
Yep. Thank you, sir. A very good morning to all of you, and thanks for attending this investors' conference call. I am pleased to brief you on the financial performance and key developments of Rainbow Children's for the fourth quarter and for the full year FY 2024-2025. Our operating revenue for the quarter stood at INR 370.1 crore, reflecting a growth of 8.5% when compared to the corresponding quarter of the previous financial year. For the full year, our revenue stood at INR 1,515.9 crore, reflecting a growth of 16.9% when compared to the previous financial year. Our EBITDA for the quarter stood at INR 114.7 crore, marking an 8.7% growth compared to the same period last year. For the full year, our EBITDA stood at INR 489.9 crore, reflecting a growth of 14.2% when compared to the previous financial year.
Our EBITDA margin for the current quarter is 31%, while for the full year, our EBITDA margin is 32.3%. The profit after tax for the quarter is INR 56.5 crore, marking a growth of 10.7% in comparison to the corresponding quarter of the last financial year. For the full year, our PAT stood at INR 244 crore, reflecting a growth of 11.9% when compared to the previous financial year. The main highlight for the year is that our cash generation from the operations for the full year remains very, very robust. Cash generation from the operations was INR 481.2 crore versus EBITDA of INR 489.8 crore, resulting in 90% conversion into the cash generation from the operations. In terms of operational performance, outpatient and inpatient volumes witnessed a growth of 3% and 4% respectively when compared to the corresponding quarter in the last financial year.
Deliveries grew by 6% compared to the corresponding period of last year. For the full year, outpatient, inpatient, and delivery volume witnessed a robust growth of 12% and 10% respectively when compared to the last financial year. Our pay mix continued to remain robust and balanced, with 52.9% of the revenue coming from the insurance and the balance 47.1% coming from the cash patients. For the full year, the pay mix stands at 48% cash and 52% insurance. I am pleased to inform that our company's balance sheet remains very robust, with cash positions of close to ₹700 crore as of March 31, 2025, and will support our ongoing capital expenditure plan. Given our current cash and anticipated internal accruals in the coming years, we will remain confident in our ability to complete all planned capital expenditures through internal accruals without any debt financing.
During the quarter, the company has invested approximately INR 43.7 crore in the capital expenditure. For the full year, the CapEx is INR 145.7 crore. With these insights, I conclude my financial updates. I now invite questions and suggestions from the participants. Thank you.
Thank you very much. We will now begin the question and answer session. Anyone who wishes to ask a question may press star and one on their touch-tone telephone. If you wish to remove yourself from the question queue, you may press star and two. Participants are requested to use handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles. The first question is from the line of Mahesh Atal from Attal Investment Advisors. Please go ahead.
Good morning, sir. My first question is more on how many beds are going to mature in the FY 2026 out of our new hospitals? How much would be shifted to our matured hospital state, and how much new would be added to the new hospitals? That is what my first question would be.
Good morning. There are two hospitals which would basically move from the new hospital category to mature hospital, which is one, the Rainbow Children's Heart Institute, and the second is the Rosewalk Hospital, and the number of beds which will basically move is 100 beds of Rainbow Children's Heart Institute and 24 beds of Rosewalk, so total 124 beds will move from new to mature category by the end of this year.
How many new would be added to the new?
Oh, about 250 beds are going to be added to the new beds, which is so there is about 150 in Bangalore, the two spokes, plus Rajahmundry of regional spoke. It's about 250 are going to add to the network, which makes it the new beds.
Okay, fair enough. My second question would be more on we could see that you are I mean, I'm not I'm failing to understand this. We have actually our new hospitals have come up, the new beds have come up. But one is that ARPOB is down in the new hospital space, but the occupancy is quite good. So, what is that we are doing? We are trying to focus more on occupancy levels right now so that you know. What is the strategy for the new hospitals going in FY 2026? How do we increase the ARPOB to the mature hospital thing?
ARPOB comes over a period of time. Whenever there's a new hospital, a new geography, a micro-market, one is that insurance will take some time. Some of your tariffs are going to be kind of a little more attractive to attract more patients to your hospital. This is a very common practice for every hospital. As the kind of hospitals, the occupancy is picking up, insurance are all boarded, then the second, third year, the pricing power increases. That's very natural for most of the new hospitals across the industry.
All right. Is there any change in the insurance rate that you have taken?
I think there is a once in two years supposed to be kind of all the renewals happen. Sometimes it can be longer also. So, periodically, as kind of they are coming in the various stages, each year someone or clusters will come into the new. We negotiate and do it. Nowadays, what we have been doing is kind of group level we do it. It's kind of a Bangalore cluster, Hyderabad cluster, and Chennai cluster. Chennai was done last year, but Bangalore is due now, and also Hyderabad is going to be done now.
Now, yes.
There is always that.
Any guidance you would like to give on the broader margins for the FY 2026?
Sir, as we kind of are in a growing franchise like this, like last year, if you recall that. So, what we have always done is about a pre-Ind AS EBITDA is about 25% EBITDA, which is something which we always guided based on our operations and also our ability to drive the growth. Whenever you have a kind of a significant number of beds added, there may be a kind of a half to a percentage of EBITDA pressure may be there. But that's what is temporary. If you look at last year, we exactly done the guidance of that this is a likely growth of late teens and 25% of pre-Ind AS EBITDA, and the margin pressure is probably about 1%, which is exactly what it panned out to be after adding 270 beds. So, we are about 0.9% of margin pressure compared to the previous year.
Just to add what Dr. Ramesh has just told is that what he is trying to say in the previous calls also. He's guided that whatever the beds we are adding, there will be definitely some pressure. But there will be threshold limits where we always foresee that our EBITDA margin pre-Ind AS will be 25%. Happy to say that for the FY 2025, though, we have added 80 beds last year, our EBITDA margin got shaved off by 0.9%. So, it stands at 26.6%, and post-Ind AS 32.3%. Again, there was a 0.8% shave-off. As we are entering this year, again, we are adding beds. Obviously, there will be some pressure of the cost from the new units, but may get partially set off from the new units which we have opened that will get set off. But it is safe to assume, as Dr.
Ramesh, CMD, is guiding that the minimum of 25% EBITDA is what is the minimum. We will try to do better as we have done this year at 26.6%.
Do you foresee any competition coming in your main spoke, I mean, main Hyderabad market?
There's always been a competition for the last 15 years' time. And cities are growing, and also population is growing. The more new hospitals are coming up, that's the natural history. And.
Is there any? Sorry to interrupt you. Is there any inorganic thing that you are looking at in Hyderabad?
In Hyderabad, no, very unlikely because we don't need to do inorganic in Hyderabad. Because if some opportunity is there, we also could do it. That's probably more efficient than going for inorganic.
Fair enough, sir, and all the best.
Thank you.
Thank you.
Thank you. Before we take the next question, we would like to remind the participants to press star and one to ask a question. The next question is from the line of Anshul Agrawal from Emkay Global. Please go ahead.
Hi, good morning, gentlemen. I hope I'm audible.
Yes, Anshul.
Yes, fine. Thank you, Anshul.
Great. So, first question is on the mature portfolio. Any comment on this performance, sir? Have occupancies been weak in a certain cluster, or is it across cluster?
Yeah, occupancy for the mature hospitals, whatever we have listed, has been slightly muted, as told in the opening remarks, right? The pediatrics was slightly muted in this March quarter. Other sides, mother care and other things was good. And Anshul, what we have always guided is if you look at our three-year CAGR or the five-year CAGR, has been very, very robust at 16%, right? And in three years or five years, when we are taking the 16% growth, it has been 12 quarters or 20 quarters. How do you see? There has been one or two quarters or three quarters where performance has not been good or subdued than the market expectations. But that is where we always catch up as a management if you look at the long-term horizon of three years and five years. So, obviously, it may be a subdued.
It doesn't show something that it is something we have to worry about, or it is something that is a long-term growth plan coming into some clouds. That is not the way. It is a one-off, and as the June quarter is progressing, we hope things will settle down, and it will catch up to our long-term trajectory of 15%-16% growth. This year is going to be very, very busy. In the next six months, as we have outlined in our presentations, a lot of capacity is getting added. We are adding 250 beds, starting with our Rajahmundry, Hennur, and Electronic City Hospital, so it is going to be very busy, which will further laid our foundations for the growth for the coming quarters.
Noted. Sir, just a follow-up on this. So, are we saying our mature portfolio should also clock around about mid-teens growth going forward, considering this is just a one-off kind of quarter?
I think that the mature hospitals usually kind of, when they do with the pricing power and those things, about 8%-10% growth, they will deliver excellent results. That's what we always see it, so for example, to a place like Hyderabad, that your 8%-10% growth is fantastic. We will deliver excellent results because they are kind of mature to the extent most of the hospitals in Hyderabad to occupancy is clocking up to 70%, so still, there's room and scope, and also, always the mature clusters will have a pricing power also, so it's a combination of things which we need to look at in the mature hospitals, and also, the case mix change also happens in the mature hospitals. These are all the combinations of our portfolio.
Great. Thank you for that detailed answer. My second question, sir, out of the new units that you had commissioned in Q4 last year, could you quantify the drag in margins from these new units in FY 2025? And have the ones in Hyderabad broken even?
Yeah. So, Anshul, the Hyderabad is breakeven. As for the guidelines which we say is a one-year for us, and then 15 or 18 months depending upon the cluster of Bangalore or Chennai, we are on the same trajectory. There is no change on that. In that regard, for the three years, the drag was at around INR 12-13 crore for the full year.
From all the four new hospitals, right?
For the three hospitals which opened last year, one each at cluster Hyderabad, Bangalore, and Chennai, the INR 12-13 crore rupees was on track.
Got it. And sir, any guidance on the Gurgaon project commissioning timeline? I heard your comments, your opening remarks, but any definitive guideline of whether it should open by FY 2028 end?
Yeah. I think I've seen originally we kind of some time ago we guided about calendar year of 2027 will probably kind of a second half of the year is the likely this one. Maybe plus or minus two, three months. So, we have taken some initiative steps to kind of speed up the project because we are taking a hybrid way of constructions with the steel column structures. So, we are trying to do all the possible things to kind of get the structures done quickly. So, once the structure is done, from there, it will probably be about one year, two months to get the rest of the things. So, we are on job. We are trying to see how we can get it done in the next two years and two years to three months. This is where we are looking at it.
26-28 months is the time we are looking at it now. This is what our project team is promising. Unless there is any other headwinds coming in between.
Got it. Very clear. Just one last question, if I may, if I can squeeze that in. So, for the next three years, sir, what would be our CapEx plan, sir? Would it be on par with what we had guided last quarter, around INR 650-odd crores in the next three years?
Yeah, it more or less remains the same. There is no change on that. So, it's on the same timelines.
Great. That's it from my end. Thank you so much. All the very best.
Thank you.
Thank you. Participants who wish to ask a question may press star and one now. The next question is from the line of Damayanti Kerai from HSBC. Please go ahead.
Hi. Good morning, and thank you for the opportunity. Just wanted to understand for the upcoming units at Rajahmundry and two units in Bangalore, have you started doctor recruitment, etc.?
Yes. We have actually done for Rajahmundry almost kind of near the closure with doctor recruitment. And Bangalore, we are on the job.
Okay. So, for all the three units, it's underway. And Rajahmundry, as you mentioned, it's broadly completed.
Yeah. The doctor team is almost closed, and also, we have kind of recruited almost about 70-plus doctors to the network in the last one year on the various specialties and surgeons and various other subspecialties.
Okay. That 70 new additions were across the network, not specific to.
Across the network. Hyderabad, Bangalore, Chennai, and Delhi.
Okay. That's helpful. And my second question is on your two recent initiatives. If you can update us on the Child Development Center and the IVF business, how these two units are picking up, and where do you see these scaling up in, let's say, three years or so?
Yeah. Well, the Child Development Center is something which kind of will take its own time. We are trying to kind of be less OP-based kind of for all the care. And we're looking for more developmental pediatricians. This is a service which we are actually trying to see that how do we cost it? How do we kind of it's very price-sensitive also because it's a long-term care. It's not a short-term care. So, we are kind of being a little slow on that. Just we don't want to see how to address the community, this burden of developmental issues and attention to all the behavioral issues. So, we are trying to get some doctors also. But one of the things is that the number of doctors trained in this area are very, very few. We got two doctors now.
We are looking for two more doctors to add. I think that's what is going to kind of change this one. It would take a little bit of time to kind of in terms of revenue size and those things. My interest is to see that how do we build a kind of a high-quality developmental service to address these children and as we move forward, I think it's probably in the next six months' time, I'll be able to kind of give you better projections of the CDC.
Okay, and on the IVF business?
Yes. So, IVF business did very well. And right now, it is 12 or 13 of the hospitals our IVF is functioning and is growing. For the year-on-year growth, because of the low base, it is very, very strong. It is more than 70% or close to 70% growth on the IVF revenue. As far as the percentage to total revenue, it still remains low, but it is moving upward. It's roughly at around close to 2.9% of the total overall revenue, which the IVF is contributing.
Okay. So, right now, under 3% of your total revenue, but it's growing, obviously, much faster.
Correct. Correct.
Okay, and my last question is on your ARPOB trajectory. So, earlier, we talked about somewhere in high single-digit growth. So, will that continue?
Yeah. That continues, definitely and also, in the various investors' calls and the meetings, what we have guided because in ARPOB, what happens is that there is a one component of ALOS, which may change because of the various reasons, right? So, what we are guiding that, what we should look at, what is the ARPP growth, basically. And for the IP ARPP growth, if you look at year-on-year on the quarter-on-quarter, year-on-year comparison basis, you'll find there is always a growth in IP ARPP. And for the last three years, we have seen there's a consistent growth in the ARPP. So, for the full year, the ARPP growth was something like at 5.6%. I think that will be the right metrics to see that one. If you look at the full-year ARPOB, it's 3.4% down, but ARPP is up by 5.6%.
I think that is the right way of looking at because the ALOS is nobody's control. It's more of operationally driven and the case-driven.
Okay. Okay. That's helpful. Thank you.
Thank you.
Thank you.
Thank you. Participants may press star and one to ask a question. The next question is from the line of Alankar Garude from Kotak Institutional Equities. Please go ahead.
Hi. Good morning, everyone. Sir, you mentioned 2.9% contribution from fertility in FY 2025. Similarly, can you comment on the broad sales split between pediatrics and maternity and fertility for the quarter?
So, the overall, the broader percentage Alankar has not changed. So, roughly 30% of our business comes from the mother care-related business, and the 70% comes from the pediatrics. So, if I'm saying mother care 30%, that includes IVF also.
Sir, but you mentioned about mother care doing well in this quarter. So, just trying to understand from a fiscal standpoint and specifically for the fourth quarter standpoint, what was the contribution of pediatrics for us?
So, as a percentage, Alankar, that is what I am saying. For the quarter, the fertility business was roughly 32%. But overall, if you see for the full year, it will come to the main reversal of 33%.
Okay. So, basically, a few percentage points here and there. Okay.
Yeah. Plus-minus here because both the specialties are growing, right?
Got it. So, the question then is, I mean, if we assume that over the next three, five years, the share of fertility and maternity increases further, should we expect the seasonality in the business coming from pediatrics to gradually reduce over the years?
Yeah. It should theoretically, yes, but our focus in growing the pediatrics also because if you have gone through our we are adding the super specialty projects in our another hub, which is Bangalore and Chennai, where we have started the transplant programs, etc. So, as those programs start in other hospitals, the pediatrics business will also start moving up, actually, on the value chain. The focus is not that we leave the pediatrics here. The focus is equally to grow that business also. This Alankar, I'm sitting here. The pediatrics is our main forte. That doesn't mean that we have no less focus on obstetrics. Our drive and focus is a lot more on pediatrics. We are the organization which is kind of we always believe that we are the people to solve pediatric healthcare for the country.
And obstetrics is a part of the pediatrics. We always say that maternal child health is one large forte. So, obstetrics comes along with the pediatrics, which is why we don't talk so much about advancing the gynecological side, gynecology, and going into too much of gynecology. It's more of a perinatal side we are interested. Of course, you do need to have some gynecology because when you have a network of patients, they require some surgical issues. We need to address that. So, we have always been very clear in our positioning of we are the children's multispecialty children's hospital, and the perinatal service is part of the children's hospitals. Unlike other people, we have absolute clarity of what we are trying to do, what we are going to do for the future.
Got it, sir. The second question is, we saw a 3% decline in RPOB in FY 2025. How should we look at RPOB growth in FY 2026? And maybe a second one related to fertility itself. Does fertility have a positive impact on RPOB?
Yes. It may be a very small piece of business, right? It's a growing business for sure. It's a smaller piece. But as we have told in the previous questions, the hospital ARPOB has multiple factors, and sometimes it may not be in control of the company because of the operational-related issues or the case, what type of case is landing at the hospital. I think the ARPP growth, if you look at, I think that is the right metrics. For the full year, if you look at, you will feel the ARPOB has come down by 3.4%. But ARPP, if you look at, has gone up by 5.6%, which is purely as a function of ALOS, which has gone up in this full year by 7.7%. So, I think the focus should be on the ARPP, which is the true reflection. ALOS is important. Obviously, it is important.
But for the timing, I think remaining focus on ARPP is important to judge our performance.
Understood, sir. So, broadly, a 5-6% number on ARPP should be something which we can pencil in.
Yeah. Yeah. Yeah.
Yes.
If we go over ALOS, then ARPOB will go up.
Got it. And one final thing, sir, one request from our end. Now that we have 19 hospitals and a sizable number across Hyderabad, Bangalore, Chennai, we have couple in AP. There's Rajahmundry also coming up. Can we please start sharing cluster-wise details? It would be really helpful if we can get some of those details to understand the numbers better, sir. Yeah. That's it from my side. Thank you.
Yeah. Well, Alankar, we'll try and give you what is the best possible way. At the end of the day, for us to see that what our annual growths of our care of our four-time impact metrics. And the question is that Hyderabad is mature. The story of Bangalore is evolving and going well. And Chennai is kind of fairly recent. When we try to compare apples to oranges, it's going to be a huge difference. We try to work around on that. And so, this is, I mean, when you give those things, it's not going to be kind of very legitimate also to kind of conclude on any of those things. So, let's allow us probably a year or so so that we will have kind of a better understanding of how it works.
Perhaps we are the only kind of proper hub-and-spoke hospital in the country which works in a very similar hub-and-spoke, truly a hub-and-spoke model. So, I mean, I will kind of let me work on this and come back to you on this. Okay? Otherwise, I will lose my hair completely.
Sure, sir. Thank you.
Thank you, Alankar.
Thank you. Understanding.
Thank you. Before we take the next question, we would like to remind the participants to press star and one to ask a question. The next question is from the line of Rahul Jeewani from IIFL Capital. Please go ahead.
Yeah. Hi, sir. Sir, of the four new hospitals which we have opened since fourth quarter of fiscal 24, you said that the Hyderabad hospitals have achieved break-even. So, can you also talk about the Chennai and the Bangalore hospitals which were opened up in, let's say, last year?
Yeah. Bangalore is fairly kind of doing very well, not very far from the break-even. And Chennai will take a little longer time because IIFL Capital and also getting a doctor team in Chennai always takes some time. So, and overall, this year, probably kind of as a combined way, all is better together. We're hoping that we'll do kind of a neutral outcome positive.
Okay. So, sir, this INR 12-13 crore EBITDA loss which you had from these hospitals in FY 2025, that will, let's say, at a combined level, will be neutral in going into 26?
Yeah. Exactly. Yeah.
Sure, sir. And sir, while you pointed out that the margins would, let's say, moderate by 50-100 basis points depending on the capacity expansion, but given that in FY 2026 and in FY 2025, we already had this base of INR 12-13 crore hitting the EBITDA which would, let's say, get to a neutral position this year. So, FY 2026, is there a possibility that FY 2026 margins would broadly be similar to FY 2025 margins?
I think so. Yeah. While expanding, I think this is what now, see, when you give a guidance, I don't want to go kind of completely haywire. So, we have always been, if you go back and see our commentary, we believe when we say that we try to do bigger than 25% EBITDA. But the 25% EBITDA is something of a benchmark which we have kept it. I mean, that's where it is we feel that nothing is not really right with Rainbow. And I mean, we would always try to achieve 26% or 26.5% EBITDA. That's our ambition, which I think most of the times we're fulfilling. So, I mean, going forward for the year also, this is what it is. Now, with the number of beds being there and what's important for me is the growth.
And a lot of beds are there in the maturing stage and great operational drive and the self-marketing drive. And we had a significant number of doctors, about 60-70 doctors in the network this year, and three more hospitals opening up. If they can do a kind of a growth of 20% or not 20%, so that will solve all the problems, whatever it is. It's not going to kind of leave any numbers which are kind of lag behind.
Sure, sir. And sir, since you pointed out that obviously our business has some seasonality, can you also talk about, let's say, how are we looking at the growth of the business from a next three-year perspective before the two Delhi hospitals get commissioned?
Sir, let's look at this broadly. I mean, the seasonality always will be there. See, when we look at, we are a medical hospital. We are not a surgical hospital. Our medical is about 75%-80%. Surgical is 20%. We are not a wear-and-tear hospital. We are more of an emergency-based, community-driven, and an emergency-driven, and seasons always play out positively and negatively, so this is how the children's hospitals worldwide evolve, but at the same time, we build our resilience and also we are increasing the large forte by adding more specialties and pediatric super specialties, intensive care services, and also quaternary care. That's the long-term story, quaternary care, so as we mature more and more, to an extent, we'll start behaving more towards a multispecialty hospital, multispecialty hospital, but it will never be like this.
It will be like multispecialty where there's a lot of businesses coming as a kind of a prefix, like cardiac or orthopedics or urology and neurosurgery and those things. Which is why your ARPOBs also keep changing with us because based on the tickets. The same ICU ticketing can be low in one year, higher next year. So, newborn ticketing can be low in one year, high next year. So, there will be kind of a when you look at the CAGR over three years or five years, I can assure you that we are growing as much as any other hospital or better than other peers. So, this is what we always kind of urgently request our analysts and investors to see that look at the CAGR rather than looking at the quarter on quarter. That is what my thing is.
When you look, I was looking at what is the CAGR for the last three years' time is about 16%. And CAGR for five years' time is about 16%.
16%.
So, there will be a kind of odd one or two quarters. There will be kind of superlative quarters, one or two quarters. So, this is how it will be. But eventually, it'll get kind of a cut off. This is the overall to give you the comprehensive picture.
Sure, sir. So, a mid-teens kind of a revenue CAGR is what we should expect going forward as well?
I would expect it to be kind of late teens to 20.
Okay. Sure, sir. Sure. And sir, obviously, our cash generation has been very good, and we have INR 700 crore of cash lying on the books. We were also evaluating inorganic opportunities in some of the markets. So, can you update us in terms of how some of those M&A discussions have been ongoing?
Oh, for sure, we have written on that. I think maybe kind of we'll come back to you very soon that we give more updates on the M&As. It's a bit premature for me to talk about them.
Okay, sir. Okay, and sir, one last question from my end. Within your core Hyderabad market, some of your peers have also announced standalone dedicated pediatric hospitals, so some of your peers are now putting up dedicated blocks within their multispecialty hospitals for pediatrics, so how do you see the competitive intensity, let's say, in your two core markets of Hyderabad and Bangalore? And do you face any challenges in terms of onboarding doctor talent for, let's say, the spokes which you are adding in these markets?
We'll have to see that when they come, actually, so it's too early to say that. We have seen this positioning, and also a couple of large multispecialties have done it in the past. A couple of large credible hospitals in Hyderabad, and I don't think they've done very well, and see, basically, it's not something that any rights of proprietorship or anything. See, essentially, if someone has gotten so much of patience to see how to build a children's hospital and have got energies and patience to do that, then it will be successful. Otherwise, it's going to be difficult, so this is how it is. You've been asking me, we have INR 700 crores on the balance sheet. I can do 1,000 beds, but would I do 1,000 beds? No. It's not possible. It's impossible for me to do 1,000 beds and make it operational.
See, if I were the multispecialty player, I would have definitely thought about it to do about 500 beds. So, there's a huge difference in how you build a multispecialty hospital and how you build a pediatric hospital which are very community-inclusive and also kind of very emergency-based.
Sure, sir. And just to follow up to that, so in the core Hyderabad market, what is the potential to add more beds, let's say, over the next three-year period? So, in the past, you have indicated that Bangalore market could potentially mirror the number of beds which we have in Hyderabad over a period of time. But within Hyderabad, let's say, do you see opportunities to further add capacities over the next three-year period, or are we sufficiently covered in Hyderabad?
We still have opportunity to do some more beds in Hyderabad. I think probably we are exploring some opportunities. Definitely, we will do some more beds in Hyderabad.
Okay, sir. Thank you. That's it from my side. Thank you.
Thanks, sir. Thank you.
Thank you. Participants, may press star and one at this time to ask a question. The next question is from the line of Manik from Findoc Investment. Please go ahead.
Hi. Thank you for the opportunity. Sir, I'm pretty new to this company. So, can you please help me with the OPD revenue and volume for FY 2025?
See, the way we look at the OPD revenue, which includes our consultation, lab, and radiology plus pharmacy, is that around 30% of our revenue comes from the OPD, and as far as the number of OPs is concerned, it's roughly 14,260,000 for the full year.
Okay. And.
Does that answer your question?
Yeah. That answers my question. And how are we surging the growth in this segment? Is it somewhere linked to the number of beds that we have, or how will it be shaped going forward?
As far as OP revenue, you are saying?
Yes, yes.
Or overall revenue?
For OP revenue.
OP revenue, I think, is overall proportionate. If you look at our last, we have seen the last few years' number, it's more or less that the ratio is the same number, plus minus 1%. So, it will get linked to overall revenue growth. And the numbers should stack up with the same number of 30% plus minus 1% of the overall revenue.
Overall revenue. Yes, correct. Understood. Thanks a lot.
Thank you.
Thank you. The next question is from the line of Nitesh Dutt from Burman Capital. Please go ahead.
Hi. Thanks for the opportunity. Just one reconfirmation. An earlier participant had asked about Gurugram timelines. I missed your response. Is it as per the schedule that you previously highlighted, or any delays in that?
Yeah. Now, we did mention when the calendar year of 2027 towards kind of the last October, November, that was actually being guided in the past. We are now having started that. We are sticking to that unless we fail to scale the way kind of we envisaged should be done by then.
Is it for both the hospitals, October, November of 2027?
Yes. More or less a couple of months plus or minus. I don't think there's going to be huge variability because there's been two projects, and also, the teams work, project teams, and everyone works together in tandem.
Understood. Thank you.
Thanks. Thank you.
Thank you. The next question is from the line of Rahul Jeewani from IIFL Capital. Please go ahead.
Yes, sir. Sir, just a clarification. This IVF revenue, which you called out as 2.9% of the revenue, was it for the quarter or for the full year?
Full year.
For the full year, Rahul, it was 2.6%. For the quarter four, it was 2.9%.
Okay. Sure, sir, and when you are talking about this, sir, so this is of the overall company revenue or the IPD revenue?
Overall revenue, Rahul.
Okay. Sure, sir. So, sir, the IVF business has scaled up pretty well given that, let's say, we started this business one and a half years or two years back. And now, this business has surpassed the international revenues which we are doing. So, what are your further plans in terms of trying to grow the IVF portfolio? So, is IVF now available across all your 19 hospitals, or there are still some hospitals where you don't offer IVF services?
I think wherever there's the possibility kind of opportunities, we would like to kind of integrate IVF within the facilities. So, right now, we are number 12, right? Isn't it?
12. Yes.
We may be kind of adding some more, but it's not on top of my head at the moment. So, one of the things which we look at is the IVF, as we do not want to go out of our campuses and do standalones too many. That is a call which we have taken because we wanted to have complete control on the clinical side of IVF, which we believe in. That is still a lot of ethical construct is very important. So, also being a hospital, the children's hospital, and also the large maternity services, we believe in organic growth and B2 C rather than B2 B. Absolutely, we are not looking at a B2 B business in the segment. It's difficult also B2 B because very unlikely an obstetrician refers to another obstetric hospital.
Okay. Sure, sir. Thank you.
Thank you.
Thank you. Participants who wish to ask a question, may press star and one now. As there are no further questions from the participants, I now hand the conference over to the management for closing comments.
Thank you for joining today's conference call and for your thoughtful questions. Your continued support is instrumental in our strategic journey, and we sincerely appreciate the time you all have invested in engaging with our business and the future directions. For any further information or clarification, you may please reach out to Mr. Saurabh Bhandari at the email ID being given in the presentations. Thank you very much.
Thank you all.
Thank you. Thank you very much. Thank you.
Thanks.
Thank you. On behalf of IIFL Capital, that concludes this conference. Thank you for joining us, and you may now disconnect your lines.
Thank you.